** = Publikationen gelistet in SCI/SSCI/Pubmed
** Zurl, H; Embacher, S; Schollnast, H; Talakic, E; Geyer, M; Schopfer-Schwab, S; Rosenlechner, D; Scheipner, L; Jasarevic, S; Seidl, M; Altziebler, J; Mannweiler, S; Riedl, J; Schwantzer, G; Ahyai, S; Mischinger, J
Prostate tumor volume is a significant predictor to identify patients with no need for concomitant systematic biopsy in men undergoing transrectal ultrasound- MRI fusion guided biopsy of the prostate
EUR UROL. Abstracts. 2023; 83(S1):S442-S442.-38th Annual EAU Congress; MAR 10-13, 2023; Milan, ITALY.
[Poster]
Web of Science
** Mischinger, J; Schöllnast, H; Zurl, H; Geyer, M; Fischereder, K; Adelsmayr, G; Igrec, J; Fritz, G; Merdzo-Hörmann, M; Elstner, J; Schmid, J; Triebl, A; Trimmel, V; Reiter, C; Steiner, J; Rosenlechner, D; Seles, M; Pichler, GP; Pichler, M; Riedl, J; Schöpfer-Schwab, S; Strobl, J; Hutterer, GC; Zigeuner, R; Pummer, K; Augustin, H; Ahyai, S; Mannweiler, S; Fuchsjäger, M; Talakic, E
Combining targeted and systematic prostate biopsy improves prostate cancer detection and correlation with the whole mount histopathology in biopsy naïve and previous negative biopsy patients.
Front Surg. 2022; 9: 1013389
Doi: 10.3389/fsurg.2022.1013389
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG